论文部分内容阅读
探讨靶向VEGF基因的不对称小干扰RNA(VEGF-asiRNA)与依诺沙星、环磷酰胺联用的抑瘤效果。通过细胞计数法、CCK-8法体外检测VEGF-asiRNA与依诺沙星和环磷酰胺对乳腺癌MCF-7细胞活力的影响。实验结果证明,与其他组相比,VEGF-asiRNA与依诺沙星和环磷酰胺联用组明显增强了对MCF-7细胞生长和增殖的抑制作用。构建胃癌BGC荷瘤裸鼠模型,分为不同实验组分别给药,14 d治疗结束后称量瘤重并计算抑瘤率。实验结果证明,脂质胶束-内皮抑素-asiRNA+依诺沙星+环磷酰胺组肿瘤体积抑制率为68.74%(P<0.01),瘤重抑制率为72.15%(P<0.01),均比其他组高。结果表明与依诺沙星、环磷酰胺联用,能够增强VEGF-asiRNA的体内外肿瘤抑制效果。
To investigate the antitumor effect of VEGF-asiRNA targeted to VEGF gene in combination with enoxacin and cyclophosphamide. The effects of VEGF-asiRNA, enoxacin and cyclophosphamide on the viability of breast cancer MCF-7 cells were examined by CCK-8 assay in vitro. Experimental results show that, compared with other groups, VEGF-asiRNA and enoxacin combined with cyclophosphamide significantly enhanced the inhibition of MCF-7 cell growth and proliferation. The gastric cancer BGC-bearing nude mice model was constructed and divided into different experimental groups, respectively. After 14 days, the tumor weight was weighed and the tumor inhibition rate was calculated. The experimental results demonstrated that the tumor volume inhibition rate was 68.74% (P <0.01) and the tumor weight inhibition rate was 72.15% (P <0.01), both of which were in the lipid micellar endostatin -asiRNA + enoxacin + cyclophosphamide group Higher than other groups. The results show that enoxacin combined with cyclophosphamide can enhance the tumor inhibitory effect of VEGF-asiRNA in vivo and in vitro.